About this trial
The goal of this observational study is to learn whether intravenous iloprost treatment for severe frostbite (grades 3-4) is feasible and safe when delivered in pre-hospital, remote high-altitude settings.
The main questions it aims to answer are:
* Is it feasible to initiate and deliver guideline-based intravenous iloprost for grade 3-4 frostbite at high altitude and what logistical barriers arise? * Does field-based initiation of iloprost increase tissue preservation and reduce amputations (compared to historical cases from similar settings)?
Participants receiving Iloprost as part of a frostbite treatment will be followed up after discharge as well as 6, 12 and 18 months to assess tissue preservation and long-term sequelae from the initial frostbite injury.
Eligibility criteria
Qualifiers
Frostbite grade 3/4 eligible for Iloprost
<72h of thawing
min. age of 18 years
provision of written informed consent
Disqualifiers
age <18 years
general contraindication
pregnancy
inability/denial to provide informed consent
Trial design
Treatments tested in this trial
- Iloprost (Ilomedin, BAYQ6256)